Missing neuropathic corneal pain means prolonged patient suffering

Written by The Life Science Feed Editorial Team · Published 20 August 2026 · Edited by Mara Voss

Neuropathic corneal pain, a chronic and debilitating condition, often leaves patients with severe ocular discomfort even after the underlying corneal injury has healed. This persistent pain, disproportionate to clinical signs, highlights a critical unmet need in ophthalmology. Effective management demands a comprehensive understanding of its complex pathophysiology and a strategic approach to treatment.

KEY TAKEAWAYS

- The Pivot: Neuropathic corneal pain is a distinct entity from nociceptive pain, requiring a shift in diagnostic and therapeutic focus.
- The Data: Treatment success often relies on a combination of topical and systemic therapies, addressing both ocular surface health and central sensitisation.
- The Action: Clinicians should consider a multi-modal strategy, integrating neuro-modulating agents and advanced ocular surface treatments, while managing patient expectations.

Neuropathic corneal pain arises from damage or dysfunction of the corneal nerves, leading to aberrant signalling within the trigeminal pathway. Unlike acute nociceptive pain, which resolves with tissue healing, neuropathic pain can persist indefinitely, driven by peripheral sensitisation, central sensitisation, and maladaptive neuroplastic changes. Patients often report burning, stinging, foreign body sensation, and photophobia, symptoms that are frequently out of proportion to objective clinical findings on slit-lamp examination. This disconnect between symptoms and signs is a hallmark of the condition, making diagnosis challenging for clinicians accustomed to correlating pain with visible pathology.
The underlying causes of neuropathic corneal pain are diverse, including previous ocular surgeries (e.g., LASIK, PRK), corneal infections, trauma, autoimmune diseases, and systemic neuropathies. A thorough patient history is paramount, focusing on prior ocular events, systemic conditions, and the quality and duration of pain. Diagnostic tools, such as in vivo confocal microscopy (IVCM) to assess corneal nerve morphology and density, and corneal aesthesiometry to quantify nerve function, can provide objective evidence of neuropathy. These tools help differentiate neuropathic pain from other forms of chronic ocular discomfort, guiding treatment selection.

Understanding the Pathophysiology

The cornea is one of the most densely innervated tissues in the body, primarily by branches of the trigeminal nerve. Damage to these nerves, whether from injury, inflammation, or surgery, can trigger a cascade of events. Peripheral sensitisation involves an increase in the excitability of nociceptors in the cornea, leading to a lowered pain threshold and exaggerated responses to stimuli. This can manifest as allodynia (pain from non-painful stimuli) or hyperalgesia

(increased pain from painful stimuli). The persistent afferent input from the damaged corneal nerves can then lead to central sensitisation within the trigeminal ganglion and brainstem, where neurons become hyperexcitable, amplifying pain signals and reducing inhibitory control. This central sensitisation explains why pain can persist even after peripheral nerve regeneration or resolution of the initial injury.

Neuroplastic changes, including sprouting of abnormal nerve fibres and alterations in neurotransmitter expression, further contribute to the chronicity of neuropathic corneal pain. The relationship between the immune system and the nervous system also plays a role, with inflammatory mediators contributing to nerve damage and sensitisation. Understanding these mechanisms is essential for developing targeted therapies that go beyond simply masking symptoms. The condition often requires a multi-pronged approach, addressing both peripheral and central components of the pain pathway.

Current Therapeutic Approaches

Treatment for neuropathic corneal pain is often complex and individualised, reflecting the varied underlying mechanisms and patient responses. Initial management typically focuses on optimising the ocular surface, as dry eye disease frequently coexists and can exacerbate neuropathic symptoms. Preservative-free artificial tears, punctal plugs, and topical anti-inflammatory agents like corticosteroids or cyclosporine are standard. Autologous serum tears, rich in growth factors and neurotrophic substances, are often employed to promote corneal nerve regeneration and reduce inflammation. These biological tears provide essential nutrients and healing factors that are absent in conventional artificial tears, supporting the health of the corneal epithelium and nerves.

But for many patients, topical treatments alone are insufficient. Systemic therapies targeting the neuropathic component are often necessary. Oral neuro-modulating agents, such as gabapentin, pregabalin, tricyclic antidepressants (e.g., amitriptyline), and serotonin-norepinephrine reuptake inhibitors (SNRIs, e.g., duloxetine), are frequently prescribed. These medications work by modulating neurotransmitter activity in the central nervous system, reducing nerve hyperexcitability and enhancing inhibitory pain pathways. Gabapentin and pregabalin, for instance, bind to the alpha-2-delta subunit of voltage-gated calcium channels, reducing the release of excitatory neurotransmitters. Tricyclic antidepressants and SNRIs increase the availability of norepinephrine and serotonin, which have analgesic effects. Dosing must be carefully titrated to balance efficacy with potential systemic side effects like somnolence, dizziness, and gastrointestinal upset.

Topical neuro-modulators, such as topical gabapentin or amitriptyline, are sometimes compounded for direct application to the ocular surface, aiming to reduce systemic side effects while delivering local therapeutic concentrations. But their efficacy and safety profiles are less established compared to their oral counterparts. Other advanced topical treatments include nerve growth factor (NGF) eye drops, which have shown promise in promoting corneal nerve regeneration and improving symptoms in some patients. NGF is a naturally occurring protein vital for nerve growth and survival, and its exogenous application can help restore damaged corneal nerves. The Oxford Handbook of Ophthalmology offers a concise overview of these and other emerging therapies.

Interventional and Emerging Strategies

When conservative and pharmacological approaches fail, interventional pain management techniques may be considered. These include trigeminal nerve blocks, radiofrequency ablation, or even surgical procedures to address specific nerve

entrapments. But these are typically reserved for refractory cases due to their invasive nature and potential complications. Neuromodulation techniques, such as transcutaneous electrical nerve stimulation (TENS) or repetitive transcranial magnetic stimulation (rTMS), are also being explored for their potential to alter central pain processing, though evidence in neuropathic corneal pain specifically remains limited.

Emerging therapies focus on novel targets. Gene therapy approaches, aiming to deliver neurotrophic factors directly to corneal nerves, are in preclinical development. Biologics that target specific inflammatory pathways or nerve receptors are also under investigation. The goal is to develop treatments that not only alleviate symptoms but also promote true nerve healing and restoration of normal corneal sensation. The challenge lies in identifying biomarkers that can predict treatment response and in conducting robust clinical trials in this often heterogeneous patient population. The lack of standardised outcome measures for neuropathic corneal pain further complicates research efforts.

The open-label nature of many early studies is an obvious caveat. The subjective nature of pain makes it susceptible to placebo effects, and without rigorous blinding and control arms, it is difficult to definitively attribute improvements solely to the intervention. The patient population for neuropathic corneal pain is relatively small and often comprises individuals with long-standing, severe symptoms, making recruitment for large-scale, well-powered trials challenging. The heterogeneity of underlying causes and pain mechanisms also means that a single treatment is unlikely to be universally effective, necessitating a personalised medicine approach.

The Unanswered Questions

Despite advances, significant gaps remain in the understanding and treatment of neuropathic corneal pain. The optimal duration of systemic neuro-modulating agents is unclear, and the long-term efficacy and safety of many emerging therapies require further investigation. Identifying specific patient phenotypes that respond best to particular treatments is a critical next step. Future research needs to focus on developing objective biomarkers of disease activity and treatment response, moving beyond subjective pain scales. This will allow for more precise diagnosis, better stratification of patients, and the development of truly targeted therapies that address the root causes of this debilitating condition.

CLINICAL IMPLICATIONS

Clinicians must recognise neuropathic corneal pain as a distinct clinical entity, separate from typical dry eye or ocular surface disease. Relying solely on topical lubricants or anti-inflammatory drops will inevitably lead to patient dissatisfaction and prolonged suffering. A proactive approach, incorporating systemic neuro-modulating agents early in the disease course, can significantly improve outcomes.

The challenge lies in managing patient expectations and navigating the side effect profiles of systemic medications. Patients need to understand that pain reduction is often gradual and that complete resolution may not be achievable. Close monitoring for adverse effects and careful dose titration are essential to maintain adherence and optimise therapeutic benefit.

Ophthalmologists should collaborate with pain specialists or neurologists when managing complex cases, particularly those refractory to initial treatments. This multidisciplinary approach can leverage expertise in systemic neuropathic pain management and offer a broader range of therapeutic options. The field needs better diagnostic tools and validated biomarkers to guide treatment selection more effectively.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. Watson SL, Le DT. Corneal neuropathic pain: a review to inform clinical practice. Eye (Lond). 2024;38(12):2350-2358. doi:10.1038/s41433-024-03060-x
2. 2. Truini A, Aleksovska K, Anderson CC, et al. Joint European Academy of Neurology-European Pain Federation-Neuropathic Pain Special Interest Group of the International Association for the Study of Pain guidelines on neuropathic pain assessment. Eur J Neurol. 2023;30(8):2177-2196. doi:10.1111/ene.15831
3. 3. Dieckmann G, Borsook D, Moulton E. Neuropathic corneal pain and dry eye: a continuum of nociception. Br J Ophthalmol. 2022;106(8):1039-1043. doi:10.1136/bjophthalmol-2020-318469
4. 4. Shanmathi AV, Yu M, Liu C, Lee IXY, Tong L, Liu YC. Electrotherapy in the management of neuropathic corneal pain: narrative review. Exp Biol Med (Maywood). 2026;251:10712. doi:10.3389/ebm.2026.10712
5. 5. Chow BJ, Yu M, Liu C, Lee IXY, Tong L, Liu YC. Vitamin abnormalities in neuropathic corneal pain. Eye Vis (Lond). 2025;12(1):39. doi:10.1186/s40662-025-00457-x
6. 6. Asiedu K. Neurophysiology of corneal neuropathic pain and emerging pharmacotherapeutics. J Neurosci Res. 2024;102(1):e25285. doi:10.1002/jnr.25285

LICENCE & RIGHTS

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED